Endovasc considers European listing strategy
This article was originally published in Clinica
Executive Summary
US drug delivery speicalist Endovasc, which has R&D programmes to develop both a drug eluting stent and a resorbable/biodegradable stent has retained corporate financier Euro Partners in order to raise its visibility among the European investment community. The company is also considering the feasibility of a dual listing in Europe in order to create a following in the stock locally.